Julphar is responsible for reporting suspected adverse reactions to the authorities of each country for medical products received from Health Care Professionals (HCP) (including but not limited to medical doctors, pharmacists, nurses, dentists, allied health professionals, midwives, caregivers etc.).
 
All queries and product related complaints are taken very seriously and treated with the strictest confidentiality. All employees of Julphar participating in the pharmacovigilance activities are trained, know their responsibility and are able to execute their duties.
 
As per Julphar policy, all employees are required to report any issues relating to the safety or quality of our medicines immediately. All spontaneous adverse events of marketed products are collected via phone, email, fax or post. All adverse events of investigational products are collected as per the Clinical Trial Protocol via above mentioned means.
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.